Belite Bio, Inc (BLTE) NASDAQ
134.93
-12.07(-8.21%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
134.93
-12.07(-8.21%)
Currency In USD
| Previous Close | 147 |
| Open | 146 |
| Day High | 146 |
| Day Low | 130.11 |
| 52-Week High | 200 |
| 52-Week Low | 56.1 |
| Volume | 383,090 |
| Average Volume | 166,215 |
| Market Cap | 5.41B |
| PE | -52.91 |
| EPS | -2.55 |
| Moving Average 50 Days | 156.49 |
| Moving Average 200 Days | 133.75 |
| Change | -12.07 |
Belite Bio to Participate in the Leerink Global Healthcare Conference
GlobeNewswire Inc.
Mar 02, 2026 1:00 PM GMT
SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have signi
Belite Bio to Host Webcast on March 2, 2026, to Discuss Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results
GlobeNewswire Inc.
Feb 23, 2026 1:00 PM GMT
SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today
Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO)
GlobeNewswire Inc.
Jan 29, 2026 1:00 PM GMT
SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have signifi